Caliway Announces Positive Phase 2 Results of CBL-514 in Dercum's Disease, Achieving Primary Endpoint with Statistically Significant and Sustained Pain Reduction

/PRNewswire/ -- Caliway Biopharmaceuticals (TWSE: 6919) on September 21 announced final statistical results from its randomized, single-blind,...

Continue in Briflio to read, react, comment, and share.